Login to Your Account



DEAL TO 'GEL' IN THIRD QUARTER

Mallinckrodt’s $5.6B Questcor Pharma buyout: Post-Cadence rhythm goes on

By Randy Osborne
Staff Writer

Tuesday, April 8, 2014
Mallinckrodt plc’s second major buy in two months – about $5.6 billion for Questcor Pharmaceuticals Inc. – created more noise than the February takeover of Cadence Pharmaceuticals Inc. for about $1.3 billion, and not just because of the larger price tag.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription